Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/19558
Title: The use of hydrogel spacer in men undergoing high-dose prostate cancer radiotherapy: results of a prospective phase 2 clinical trial.
Authors: Chao, Michael;Lim Joon, Daryl;Khoo, Vincent;Lawrentschuk, Nathan L;Ho, Huong;Spencer, Sandra;Chan, Yee;Tan, Alwin;Pham, Trung;Sengupta, Shomik;McMillan, Kevin;Liu, Madalena;Koufogiannis, George;Cham, Chee Wee;Foroudi, Farshad;Bolton, Damien M
Affiliation: The Valley Private Hospital, Mulgrave, Australia
The Box Hill Hospital, Box Hill, Australia
Genesis Cancer Care Victoria, 36 Mt Dandenong Road, Ringwood East, VIC, 3135, Australia
Austin Health, Heidelberg, Victoria, Australia
University of Melbourne, Melbourne, Australia
Monash University, Melbourne, Australia
Royal Marsden Hospital, London, UK
The Bays Hospital, Mornington, Australia
Ringwood Private Hospital, Ringwood East, Australia
Issue Date: 24-Sep-2018
EDate: 2018-09-24
Citation: World journal of urology 2018; online first: 24 September
Abstract: The purpose of this study was to determine whether the degree of prostate to rectal separation using a hydrogel spacer (HS) and its effect on decreasing rectal dose can be reproduced in the community setting. Thirty one patients with cT1-3aN0M0 prostate adenocarcinoma receiving radical radiotherapy to 78 Gy were recruited to the study. The primary endpoint was the proportion of patients achieving at least 25% reduction in volume of rectum receiving 70 Gy (rV70). Other endpoints included degree of prostate to rectum separation, HS insertion-related adverse events and the proportion of patients with grade 1 or worse acute or late gastrointestinal (GI) and genitourinary (GU) toxicity. All patients had successful insertion of their HS with no peri-operative toxicity. The mean prostate-rectal separation achieved was 10.5 mm. Twenty nine (93.5%) patients achieved a reduction in rV70 of at least 25%. Acute grade 1 GI toxicity was reported in 3 patients. All symptoms had resolved by 3 months post RT. Late grade 1 GI toxicity was reported in one patient (3.2%) with bowel frequency occurring at 6 months and resolving by 12 months post RT. There was no grade 2 or 3 acute or late GI toxicity seen. In conclusion, this study illustrates that the application and benefits of HS on reducing GI rectal dose endpoints and toxicities during prostate cancer RT can be reliably replicated in a community setting similar to centres participating in the randomised trial under high quality assurance trial monitoring.
URI: http://ahro.austin.org.au/austinjspui/handle/1/19558
DOI: 10.1007/s00345-018-2502-5
ORCID: 0000-0002-5145-6783
0000-0002-3497-3746
0000-0001-8553-5618
0000-0003-3357-1216
0000-0001-8387-0965
PubMed URL: 30251049
Type: Journal Article
Subjects: Hydrogel spacer
Prostate cancer
Radiotherapy
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.